Objective To evaluate the efficacy of minimally invasive perventricular device closure of ventricular septal defect(VSD). Methods Between September 2011 and February 2013, we collected 40 patients who underwent perven...Objective To evaluate the efficacy of minimally invasive perventricular device closure of ventricular septal defect(VSD). Methods Between September 2011 and February 2013, we collected 40 patients who underwent perventricular closure via a small lower sternal incision(minimally invasive group), aged 15.5±3.5 years(12 months to 32 years) with a body weight of 24.2±7.5 kg(10.8-58.0 kg). The mean size of VSD was 5.6±0.5 mm(2-14 mm). Another 40 patients were included as the surgical group, receiving the conventional surgical repair of VSD. The device of the minimally invasive group was released under the guidance of transesophageal echocardiography. Success rate, cardiac indicators, and clinical outcomes of the 2 groups were compared. Results The patients in the surgical group and those in the minimally invasive group showed similar results in success rate(both 97.5%). The procedure time, intensive care unit stay, hospital stay, and postoperative recovery time in the minimally invasive group were significantly shorter than those in the surgical group(58±21 minutes versus 145±26 minutes, 2±1 days versus 8±3 days, 5±1 days versus 16±6 days, 3±1 days versus 90±20 days, all P<0.05). The minimally invasive group had a higher incidence of conduction anomalies(17.5% versus 2.5%, P<0.05). In the follow-up period of 3-12 months, there was no new residual shunt, noticeable aortic regurgitation, significant arrhythmias, or device failure except for new complications in the surgical group. Conclusions The success rate of minimally invasive perventricular device closure of VSD under transesophageal echocardiography guidance is similar to that of conventional surgical repair, but the short-term outcomes of the minimally invasive approach is much better. Long-term follow-up is necessary to confirm the effectiveness of this technique.展开更多
目的探讨血必净注射液联合地塞米松磷酸钠注射液治疗重症脓毒症的临床疗效。方法选取2023年1~12月重庆大学附属涪陵医院收治的66例重症脓毒症患者临床资料,根据用药方案不同分为对照组和治疗组,各33例。对照组静脉滴注地塞米松磷酸钠注...目的探讨血必净注射液联合地塞米松磷酸钠注射液治疗重症脓毒症的临床疗效。方法选取2023年1~12月重庆大学附属涪陵医院收治的66例重症脓毒症患者临床资料,根据用药方案不同分为对照组和治疗组,各33例。对照组静脉滴注地塞米松磷酸钠注射液,10 mg地塞米松注射液与250 m L 5%葡萄糖混合,1次/d。治疗组在对照组基础上静脉滴注血必净注射液,100 mL血必净注射液与250 mL 5%葡萄糖混合,2次/d。两组共治疗1周。比较两组临床疗效、临床症状改善时间、疾病严重程度、血清炎症因子。结果治疗后,治疗组的总有效率为90.91%,高于对照组总有效率63.64%(P<0.05)。治疗后,治疗组完成复苏时间、血压复常时间、体温恢复时间均短于对照组(P<0.05)。治疗后,两组急性生理学与慢性健康状况评价系统Ⅱ(APACHEⅡ)评分均低于治疗前(P<0.05),且治疗组患者的APACHEⅡ评分低于对照组(P<0.05)。治疗后,两组血清白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)水平均低于治疗前(P<0.05),且治疗组血清CRP、IL-6、TNF-α水平低于对照组(P<0.05)。结论重症脓毒症采用血必净注射液联合地塞米松磷酸钠注射液治疗的疗效显著,可缩短患者临床症状改善时间,降低患者病情严重程度和炎症水平。展开更多
文摘Objective To evaluate the efficacy of minimally invasive perventricular device closure of ventricular septal defect(VSD). Methods Between September 2011 and February 2013, we collected 40 patients who underwent perventricular closure via a small lower sternal incision(minimally invasive group), aged 15.5±3.5 years(12 months to 32 years) with a body weight of 24.2±7.5 kg(10.8-58.0 kg). The mean size of VSD was 5.6±0.5 mm(2-14 mm). Another 40 patients were included as the surgical group, receiving the conventional surgical repair of VSD. The device of the minimally invasive group was released under the guidance of transesophageal echocardiography. Success rate, cardiac indicators, and clinical outcomes of the 2 groups were compared. Results The patients in the surgical group and those in the minimally invasive group showed similar results in success rate(both 97.5%). The procedure time, intensive care unit stay, hospital stay, and postoperative recovery time in the minimally invasive group were significantly shorter than those in the surgical group(58±21 minutes versus 145±26 minutes, 2±1 days versus 8±3 days, 5±1 days versus 16±6 days, 3±1 days versus 90±20 days, all P<0.05). The minimally invasive group had a higher incidence of conduction anomalies(17.5% versus 2.5%, P<0.05). In the follow-up period of 3-12 months, there was no new residual shunt, noticeable aortic regurgitation, significant arrhythmias, or device failure except for new complications in the surgical group. Conclusions The success rate of minimally invasive perventricular device closure of VSD under transesophageal echocardiography guidance is similar to that of conventional surgical repair, but the short-term outcomes of the minimally invasive approach is much better. Long-term follow-up is necessary to confirm the effectiveness of this technique.
文摘目的探讨血必净注射液联合地塞米松磷酸钠注射液治疗重症脓毒症的临床疗效。方法选取2023年1~12月重庆大学附属涪陵医院收治的66例重症脓毒症患者临床资料,根据用药方案不同分为对照组和治疗组,各33例。对照组静脉滴注地塞米松磷酸钠注射液,10 mg地塞米松注射液与250 m L 5%葡萄糖混合,1次/d。治疗组在对照组基础上静脉滴注血必净注射液,100 mL血必净注射液与250 mL 5%葡萄糖混合,2次/d。两组共治疗1周。比较两组临床疗效、临床症状改善时间、疾病严重程度、血清炎症因子。结果治疗后,治疗组的总有效率为90.91%,高于对照组总有效率63.64%(P<0.05)。治疗后,治疗组完成复苏时间、血压复常时间、体温恢复时间均短于对照组(P<0.05)。治疗后,两组急性生理学与慢性健康状况评价系统Ⅱ(APACHEⅡ)评分均低于治疗前(P<0.05),且治疗组患者的APACHEⅡ评分低于对照组(P<0.05)。治疗后,两组血清白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)水平均低于治疗前(P<0.05),且治疗组血清CRP、IL-6、TNF-α水平低于对照组(P<0.05)。结论重症脓毒症采用血必净注射液联合地塞米松磷酸钠注射液治疗的疗效显著,可缩短患者临床症状改善时间,降低患者病情严重程度和炎症水平。
